A high prevalence of TP53 mutations has been observed in cancers with WGD, particularly in early-onset colorectal cancer (EO-CRC), suggesting that the early loss of the p53 function enhances the survival of cells after WGD [133] (Figure 2B). The gene discussed is TP53; the disease is cancer.